Materiovigilance Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Materiovigilance Market Trends and Insights

Expansion of Mandatory Device Incident Reporting

Mandatory incident reporting is moving from a compliance backstop to a central source of demand in the materiovigilance market. The European Commission made 4 EUDAMED modules compulsory from May 28, 2026, covering actor registration, UDI and device registration, notified bodies and certificates, and market surveillance. These requirements direct manufacturers, authorized representatives, importers, and notified bodies toward a shared digital reporting structure. The FDA Quality Management System Regulation became effective on February 2, 2026, and incorporated ISO 13485:2016 into 21 CFR Part 820. Smaller manufacturers face a greater need for external reporting platforms and managed services because they may lack dedicated regulatory resources. The materiovigilance market benefits from obligations that continue regardless of device demand cycles or broader economic conditions.

Cloud Consolidation of Complaint, Vigilance, and PMS Data

Cloud adoption supports regulatory readiness because surveillance records must remain current, connected, and accessible across reporting locations. The materiovigilance market is favoring platforms that bring complaint data, field safety corrective actions, clinical follow-up records, and risk documentation into one controlled workflow. This arrangement can reduce manual handoffs between case intake, corrective action, and surveillance teams. It also supports the documented quality systems required under the FDA QMSR, which now incorporates ISO 13485:2016. Providers can strengthen client retention when reporting taxonomies, regulatory rules, and periodic safety report templates are configured within the same environment. The value of cloud consolidation is limited in locations where patient identifiers and related safety data must remain within national or regional boundaries.

AI-Assisted Signal Detection From Unstructured Complaints

The growing volume of complaint narratives makes manual review harder to complete within regulatory reporting periods. AI-supported triage can extract adverse-event labels from unstructured text and prepare information for more consistent review. A 2025 study reported that PVLens achieved an F1 score of 0.88 for automated adverse-event label extraction. Research based on FDA MAUDE data found that AI and machine-learning device reports differed from reports for conventional devices, which points to a need for updated signal-detection methods. An ISPOR presentation in 2026 reported content validity of Aiken’s V = 0.85 and reliability of Cronbach’s alpha from 0.68 to 0.77 for an AI-integrated causality assessment tool across 70 cases^{[1]ISPOR, “SMART SAFETY: Integrating AI with the Materiovigilance Causality Assessment Tool for Enhanced Medical Device Monitoring,” ISPOR AP Summit 2026, ispor.org}. Providers that add duplicate detection, case routing, and completeness checks can respond to this operational need within the materiovigilance market.

Rising Complexity of Connected and Software-Enabled Devices

Connected devices and software as a medical device require teams to monitor software behavior alongside physical device failures. The EU AI Act adds high-risk and substantial-modification obligations for relevant AI-enabled devices, alongside existing medical-device requirements. The cited analysis described an emergency-admission AI model whose AUC declined from 0.86 to 0.83 during the COVID-19 pandemic without a visible malfunction. This type of model drift cannot be reliably captured through spontaneous reports alone. FDA clearances for more than 870 AI and machine-learning medical devices by mid-2023 added to the ongoing surveillance workload for deployed products. The materiovigilance market has room for platforms that incorporate ongoing drift detection, calibration review, and model-performance controls into standard post-market processes.

Fragmented Reporting Taxonomies and Cross-Border Rules

The materiovigilance market must operate across national reporting rules that differ in classifications, filing languages, data fields, and submission deadlines. A 2025 review found continuing differences between the European Union’s EudraVigilance and EUDAMED structures and the more centralized U.S. FAERS and MAUDE approach. A manufacturer selling a device in 15 jurisdictions may need 15 differently formatted periodic safety reports and separate regulatory contacts. These requirements raise the effort needed to design and validate global reporting software. The burden falls most heavily on mid-size OEMs that do not have the regulatory affairs capacity of larger multinational companies. As a result, some manufacturers may concentrate surveillance investment in their largest sales jurisdictions, which can leave gaps in global safety records.

Cybersecurity, Privacy, and Data-Residency Exposure

Materiovigilance systems process patient information and incident narratives, so privacy and security controls are fundamental to their use. The FDA describes cybersecurity considerations for medical devices across the product lifecycle, including premarket and postmarket activities^{[2]U.S. Food and Drug Administration, “Cybersecurity,” U.S. Food and Drug Administration, fda.gov}. Cross-border deployments must also address GDPR duties in Europe and data-residency requirements in China and India. These obligations can require regional data storage, controlled access, and coordinated incident-response procedures. The cost of meeting these requirements across several jurisdictions favors providers with established regional infrastructure. Security reviews and validation expectations can also lengthen the adoption process for new systems in the materiovigilance market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Service Type: Regulatory Compliance Reporting Outpaces Legacy Adverse Event Functions

Adverse Event Reporting held 44.31% of the materiovigilance market share in 2025 because it remains the legally required base of device post-market surveillance. The FDA MAUDE system and the EUDAMED vigilance framework require timely reporting of relevant events. Missed reporting obligations can lead to inspection scrutiny and other compliance consequences. Post-Market Surveillance services support structured evidence collection rather than only reactive complaint handling. Risk Assessment and Management services support ongoing review of device risks and benefits. Material Safety Monitoring also addresses biocompatibility information and early signs of product issues.

Regulatory Compliance and Reporting is forecast to grow at a 12.65% CAGR through 2031. The materiovigilance market is being shaped by concurrent implementation of EUDAMED requirements and the U.S. QMSR. The service can become a broader entry point when OEMs expand from case processing to inspection preparation and regulatory documentation. Countries such as India, Australia, Canada, and the United States have established post-marketing systems, while other locations are still developing similar structures. This uneven maturity creates demand for providers that can apply requirements across jurisdictions. Documentation linkages under ISO 13485:2016 further support the need for integrated compliance services.

By Delivery Mode: Hybrid Architectures Gain Ground as Data Localization Pressures Mount

Cloud-Based delivery accounted for 66.24% of the materiovigilance market size in 2025. It supports large reporting volumes, multi-site coordination, and real-time aggregation of complaint and surveillance information. Cloud platforms can also embed regulatory rules that reduce the specialized expertise required to maintain current workflows. This feature is important for mid-size OEMs managing changing U.S. and European requirements. On-Premise delivery remains relevant for large OEMs, public institutions, and national health authorities with strict data-sovereignty controls. It is also relevant where rules restrict transfers of identifiable health information outside a country or region.

Hybrid deployment is forecast to grow at a 13.42% CAGR through 2031. This approach combines cloud-based analytics and signal detection with local storage for sensitive patient identifiers. It responds to the need for analysis at scale while respecting local data controls in Asia-Pacific, the Middle East, and Europe. Hybrid configurations can increase switching costs because a new provider must revalidate connections between local infrastructure and analytical systems. AB Cube’s 2026 roadmap highlighted security, resilience, and future-readiness features, including CasEasy V3 and Converter V2. These product investments reflect the emphasis on configurations that can serve different data-control requirements.

By Device Type: Diagnostic Devices Lead, But Therapeutic Portfolio Complexity Commands Faster Investment

Diagnostic Devices held 42.14% of the materiovigilance market share in 2025. Their position reflects the breadth of instruments in use, including in vitro diagnostic platforms and AI-supported radiology tools. The range of product types produces varied complaint categories and monitoring requirements. This requires structured intake, assessment, and signal detection capabilities. Surgical Devices carry intensive post-approval surveillance needs because of their higher-risk applications. Monitoring Devices also require attention to connectivity, cybersecurity, and software updates in addition to traditional safety reporting.

Therapeutic Devices is forecast to grow at a 9.42% CAGR through 2031. Implantable and connected therapeutic products can generate continuous data on performance and safety, rather than only discrete incident records. Combination products used in oncology, neurology, and chronic disease management require drug and device reporting workflows at the same time. This increases the need to align EudraVigilance and FAERS drug reporting with EUDAMED and MAUDE device reporting. The materiovigilance market is therefore responding to a broader set of therapeutic safety and compliance requirements.

By End User: OEMs Drive Volume, But Public Health Programs Set the Regulatory Agenda

Original Equipment Manufacturers held 44.61% of the materiovigilance market size in 2025. Their obligations include adverse-event reporting, post-market surveillance, periodic safety reports, and related documentation. These requirements make OEMs demand a predictable source of revenue for software and service providers. Contract Research Organizations and Business Process Outsourcing Providers handle overflow work when OEM portfolios expand faster than in-house teams. Healthcare institutions are also becoming more relevant buyers when reporting duties create a need for local reporting coordination. The combined requirements support a continued role for managed services across the materiovigilance industry.

Regulatory Authorities and Public-Health Programs are forecast to expand at a 13.25% CAGR through 2031. Public bodies are investing in surveillance capacity as national vigilance programs become more formalized. India’s Indian Pharmacopeia Commission reinforced adverse-event reporting compliance under the Materiovigilance Program of India in February 2026^{[3]Indian Pharmacopoeia Commission, “Strengthening Adverse Event Reporting Under the Materiovigilance Programme of India (MvPI),” Indian Pharmacopoeia Commission, ipc.gov.in}. Uppsala Monitoring Center’s VigiLyze serves national pharmacovigilance centers and regulatory authorities participating in the WHO Program for International Drug Monitoring. Public-sector accounts can be embedded in national surveillance programs over several years. That structure can make these accounts harder to replace than commercial contracts affected by mergers or portfolio changes.

Geography Analysis

North America held 38.42% of the materiovigilance market share in 2025. The region benefits from an established adverse-event reporting infrastructure and a dense U.S. medical-device ecosystem. The FDA QMSR took effect in February 2026 and incorporated ISO 13485:2016 into 21 CFR Part 820. U.S. demand includes enterprise quality management platforms, AI-supported signal tools, and contract research organization services. FDA cybersecurity guidance also supports investment in systems that connect safety reporting with connected-device and software-update records.

Europe remains an important geography because the EU MDR provides a shared regulatory baseline for the 27-member market. Germany, France, the United Kingdom, Italy, and Spain provide much of the region’s demand. EUDAMED’s first 4 modules become mandatory on May 28, 2026, which increases the need for coordinated digital reporting. The United Kingdom retains a separate MHRA framework after Brexit, creating additional submission requirements for manufacturers operating in both systems. Germany’s medical-device manufacturing base supports domestic demand for platform and service providers. The region also faces scrutiny of privacy, security, and data-transfer controls.

Asia-Pacific is forecast to grow at a 12.33% CAGR through 2031. The region’s expansion reflects stronger reporting expectations and a growing device base in China, India, South Korea, and Japan. India’s February 2026 notice reinforced reporting compliance for medical-device marketing authorization holders under MvPI. Japan and South Korea are mature enforcement-focused systems, so their contribution is more incremental. The Middle East and Africa remain early-stage areas supported by healthcare investment and regional partnerships. South America is supported by Brazil’s ANVISA framework and Argentina’s evolving regulatory structure.